特讯热点！《速度与激情10》免费抢票活动火爆开启，新浪观影团邀您共赴速度盛宴

《速度与激情10》免费抢票活动火爆开启，新浪观影团邀您共赴速度盛宴

北京 - 2023年5月11日，由新浪观影团主办的《速度与激情10》免费抢票活动正式开启，活动一经推出便引起了广大影迷的热烈关注。

《速度与激情》系列电影以其热血刺激的飙车场面和跌宕起伏的剧情而闻名，深受全球观众喜爱。此次《速度与激情10》的免费抢票活动，为影迷们提供了难得的零成本观影机会，也让更多人有机会感受这部年度巨制的魅力。

活动规则十分简单，关注@新浪观影团 并转发活动微博，即可参与抽奖。活动奖品为《速度与激情10》电影票，获奖名额共53人。

活动于5月16日中午12点截止，获奖名单将于5月17日公布。获奖者需于5月17日下午6点前持本人身份证至北京UME影城华星店领取电影票。

《速度与激情10》将于2023年5月17日在中国大陆上映，该片由路易斯·莱特里尔执导，范·迪塞尔、米歇尔·罗德里格兹、泰瑞斯·吉布森等主演。影片将讲述唐老大（范·迪塞尔饰）带领飞车家族再次集结，对抗强大的新敌人的故事。

新浪观影团表示，希望通过此次活动，为影迷们带来福利，也让更多人关注到《速度与激情10》这部电影。

关于新浪观影团

新浪观影团是新浪微博旗下专业电影资讯平台，致力于为用户提供最新电影资讯、专业影评、观影福利等。新浪观影团拥有众多资深影评人和电影爱好者，为用户提供优质的观影体验。

媒体联系方式

新浪观影团

电话：010-82611234

[移除了电子邮件地址]

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.